Effect of integrin receptor‑targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapy Retraction in /10.3892/ol.2021.12611

Chen,Liyu; Liu,Yanbin; Wang,Weiya; Liu,Kai

doi:10.3892/ol.2015.3242

Effect of integrin receptor‑targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapy

Retraction in: /10.3892/ol.2021.12611

Authors:
- Liyu Chen
- Yanbin Liu
- Weiya Wang
- Kai Liu
View Affiliations

Affiliations: Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: May 20, 2015 https://doi.org/10.3892/ol.2015.3242
Pages: 77-84
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The major aim of the present study was to develop an integrin receptor‑targeted liposomal paclitaxel (PTX) to enhance the targeting specificity and therapeutic effect of PTX on hepatocellular carcinoma (HCC) cells. The specific Arg‑Gly‑Asp (RGD) ligand was conjugated to 1,2‑distearoylphosphatidylethanolamine‑polyethylene glycol 2000 to prepare the RGD‑modified liposomes (RGD‑LP). Furthermore, physicochemical characteristics of RGD‑LP, including particle size, ζ potential, encapsulation efficiency and in vitro PTX release, were evaluated. RGD‑modified liposomes were selected as the carrier for the present study, as they exhibit good biocompatibility and are easy to modify using RGD. The cellular uptake efficacy of RGD‑LP by HepG2 cells was 3.3‑fold higher than that of liposomes without RGD, indicating that RGD‑LP may specifically target HepG2 cells by overexpressing integrin αvβ3 receptors. The RGD modification appeared to enhance the anti‑proliferative activity of LP‑PTX against HepG2 cells, with the extent of anti‑proliferative activity dependent on the concentration of PTX and the incubation time. Additionally, evaluation of the homing specificity and anticancer efficacy of RGD‑LP on the tumor spheroids indicated that solid tumor penetration was enhanced by the modification of RGD. In agreement with these in vitro findings, in vivo investigations demonstrated that RGD‑LP‑PTX exhibited a greater inhibitory effect on tumor growth in HepG2‑bearing mice than LP‑PTX or free PTX. Thus, RGD‑LPs may represent an efficient targeted PTX delivery system for the treatment of patients with HCC.

View Figures

View References

1	Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer. 6:674–687. 2006. View Article : Google Scholar : PubMed/NCBI
2	Liu X, Wang W and Wang Z: Recent progress in understanding the effects of autophagy in hepatocellular carcinoma. Chin J Hepatobil Surg. 20:69–73. 2014.
3	Pan Y, Ye S, Yuan D, et al: Hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells. Mutat Res. 763–764:10–18. 2014. View Article : Google Scholar
4	Zhang C, He H, Zhang H, et al: The blockage of Ras/ERK pathway augments the sensitivity of SphK1 inhibitor SKI II in human hepatoma HepG2 cells. Biochem Biophys Res Commun. 434:35–41. 2013. View Article : Google Scholar : PubMed/NCBI
5	Baek JS, So JW, Shin SC and Cho CW: Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system. Int J Mol Med. 30:953–959. 2012.PubMed/NCBI
6	Sun J, Deng L, Duan Y, et al: Inhibitory effect of endostatin combined with paclitaxel-cisplatin on breast cancer in xenograft-bearing mice. Exp Ther Med. 3:159–164. 2012.PubMed/NCBI
7	Kimura K, Tanaka S, Iwamoto M, et al: Safety of nanoparticle albumin-bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports. Oncol Lett. 6:881–884. 2013.PubMed/NCBI
8	Tanaka T, Toujima S and Tanaka J: Differential sensitivity to paclitaxel-induced apoptosis and growth suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial adenocarcinoma cells. Int J Oncol. 41:1837–1844. 2012.PubMed/NCBI
9	Tsukada T, Fushida S, Harada S, et al: Low-dose paclitaxel modulates tumour fibrosis in gastric cancer. Int J Oncol. 42:1167–1174. 2013.PubMed/NCBI
10	Horwitz SB: Taxol (paclitaxel): Mechanisms of action. Ann Oncol. 5 (Suppl 6):S3–S6. 1994.PubMed/NCBI
11	Liebmann J, Cook JA and Mitchell JB: Cremophor EL, solvent for paclitaxel and toxicity. Lancet. 342:14281993. View Article : Google Scholar : PubMed/NCBI
12	Gou Y, Wang L, Lv P and Zhang P: Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer. Oncol Lett. 9:1065–1072. 2015.PubMed/NCBI
13	Despierre E, Lambrechts D, Neven P, et al: The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol Oncol. 117:358–365. 2010. View Article : Google Scholar : PubMed/NCBI
14	Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer AR, Fowler WC Jr, Malfetano JH and Alvarez RD: Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A Gynecologic Oncology Group study. J Clin Oncol. 19:1275–1278. 2001.PubMed/NCBI
15	McGuire WP, Blessing JA, Moore D, Lentz SS and Photopulos G: Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol. 14:792–795. 1996.PubMed/NCBI
16	Rose PG, Blessing JA, Gershenson DM and McGehee R: Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol. 17:2676–2680. 1999.PubMed/NCBI
17	Chua DT, Sham JS and Au GK: A phase II study of docetaxel and cisplatin as first line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 41:589–595. 2005. View Article : Google Scholar : PubMed/NCBI
18	McCarthy JS, Tannock IF, Degendorfer P, Panzarella T, Furlan M and Siu LL: A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol. 38:686–690. 2002. View Article : Google Scholar : PubMed/NCBI
19	Yin Y, Wu X, Yang Z, et al: The potential efficacy of R8-modified paclitaxel-loaded liposomes on pulmonary arterial hypertension. Pharm Res. 30:2050–2062. 2013. View Article : Google Scholar : PubMed/NCBI
20	Wender PA, Galliher WC, Goun EA, Jones LR and Pillow TH: The design of guanidinium-rich transporters and their internalization mechanisms. Adv Drug Deliv Rev. 60:452–472. 2008. View Article : Google Scholar : PubMed/NCBI
21	Lee JH, Engler JA, Collawn JF and Moore BA: Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem. 268:2004–2012. 2001. View Article : Google Scholar : PubMed/NCBI
22	Oba M, Fukushima S, Kanayama N, et al: Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing alphavbeta3 and alphavbeta5 integrins. Bioconjug Chem. 18:1415–1423. 2007. View Article : Google Scholar : PubMed/NCBI
23	Li S, Wei J, Yuan L, et al: RGD-modified endostatin peptide 530 derived from endostatin suppresses invasion and migration of HepG2 cells through the αvβ3 pathway. Cancer Biother Radiopharm. 26:529–538. 2011. View Article : Google Scholar : PubMed/NCBI
24	Kibria G, Hatakeyama H, Ohga N, et al: Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release. 153:141–148. 2011. View Article : Google Scholar : PubMed/NCBI
25	Sharma G, Modgil A, Sun C and Singh J: Grafting of cell-penetrating peptide to receptor-targeted liposomes improves their transfection efficiency and transport across blood-brain barrier model. J Pharm Sci. 101:2468–2478. 2012. View Article : Google Scholar : PubMed/NCBI
26	Jiang T, Zhang Z, Zhang Y, et al: Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials. 33:9246–9258. 2012. View Article : Google Scholar : PubMed/NCBI
27	Maeda N, Takeuchi Y, Takada M, et al: Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J Control Release. 100:41–52. 2004. View Article : Google Scholar : PubMed/NCBI
28	Zhang Q, Tang J, Fu L, et al: A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system. Biomaterials. 34:7980–7993. 2013. View Article : Google Scholar : PubMed/NCBI
29	Qin Y, Chen H, Yuan W, et al: Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm. 419:85–95. 2011. View Article : Google Scholar : PubMed/NCBI
30	Borgne-Sanchez A, Dupont S, Langonné A, et al: Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of alphaVbeta3-expressing endothelial cells. Cell Death Differ. 14:422–435. 2007. View Article : Google Scholar : PubMed/NCBI
31	Lewis CE and Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66:605–612. 2006. View Article : Google Scholar : PubMed/NCBI
32	Fukumura D, Xu L, Chen Y, et al: Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 61:6020–6024. 2001.PubMed/NCBI
33	Jain RK: Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 46:149–168. 2001. View Article : Google Scholar : PubMed/NCBI